Hepatitis C Virus–Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report

Abstract

Letters7 March 2017Hepatitis C Virus–Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case ReportLazzaro di Biase, MD, Marina Picillo, MD, Maria Eliza Freitas, MD, Esther Bui, MD, and Alfonso Fasano, MD, PhDLazzaro di Biase, MDFrom Campus Bio-Medico University of Rome, Rome, Italy; University of Salerno, Salerno, Italy; and Toronto Western Hospital and University Health Network, and University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, Marina Picillo, MDFrom Campus Bio-Medico University of Rome, Rome, Italy; University of Salerno, Salerno, Italy; and Toronto Western Hospital and University Health Network, and University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, Maria Eliza Freitas, MDFrom Campus Bio-Medico University of Rome, Rome, Italy; University of Salerno, Salerno, Italy; and Toronto Western Hospital and University Health Network, and University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, Esther Bui, MDFrom Campus Bio-Medico University of Rome, Rome, Italy; University of Salerno, Salerno, Italy; and Toronto Western Hospital and University Health Network, and University of Toronto, Toronto, Ontario, Canada.Search for more papers by this author, and Alfonso Fasano, MD, PhDFrom Campus Bio-Medico University of Rome, Rome, Italy; University of Salerno, Salerno, Italy; and Toronto Western Hospital and University Health Network, and University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0038 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Hepatic myelopathy is a rare complication of advanced-phase liver dysfunction (1). The most common presentation is spastic paraparesis, which is associated with variable sensory deficits (2). Hepatic myelopathy is a progressive, disabling condition that may reverse if normal liver function is restored—for example, after transplantation (Appendix Table) (2). Sofosbuvir is a novel nucleotide analogue that inhibits the NS5B polymerase of hepatitis C virus (HCV). Sofosbuvir produces a high rate of sustained virologic response when used to treat HCV infection (3).Appendix Table. Outcome of Reported Patients With Hepatic Myelopathy Objective: ...